Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) was submitted on March 18, 2022, reporting an event that occurred on March 17, 2022. The Company is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
On March 17, 2022, Nasdaq notified the Company that its common stock bid price had closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This constitutes a failure to satisfy a continued listing rule.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days, until September 13, 2022, to regain compliance. Compliance is achieved if the bid price closes at $1.00 or more for 10 consecutive business days.
- Secondary Compliance Option: If the initial deadline is missed, the Company may be eligible for an additional 180-day period, provided it meets market value and other initial listing standards. This may require a reverse stock split.
- Delisting Risk: Failure to regain compliance by the required deadlines will result in written notification of delisting. The Company retains the right to appeal such a determination to a Nasdaq hearings panel.
- Current Status: The notice has no immediate effect on the listing; the stock continues to trade under the symbol "AVTX."
- Management Action: The Company is currently evaluating options to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current bid price of AVTX common stock to assess progress toward the $1.00 threshold.
- Monitor the Company's announcements regarding potential reverse stock splits or other capital structure changes.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if needed.
- Track the September 13, 2022, deadline for the initial compliance period.